25 results on '"Gonzalez, Derlis"'
Search Results
2. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials
3. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease
4. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach
5. eP148: Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
6. Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
7. Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
8. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study
9. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease
10. Long-term treatment of Gaucher disease with velaglucerase alfa in a cohort of patients from Paraguay
11. Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study
12. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial
13. Response to request by journal editorship from Blood Cells , Molecules and Diseases in reference to a “Dear Editor” letter to the Pastores et al. paper, 2016
14. PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study
15. One-year follow up of Fabry disease patients treated by IV administration of a plant derived alpha-Gal-A enzyme: safety and efficacy
16. Therapeutic goals and normal clinical values achieved within 4years of initiating velaglucerase alfa in treatment-naïve patients with Gaucher disease in phase 3 studies
17. Novel treatment for Fabry disease: IV administration of plant derived alpha-gal-A enzyme safety and efficacy interim report
18. Hematopoietic Stem Cell Transplant Activity in Latin America: Predominant Increase in Autologous and Modest Increase in Allogeneic HCT with High Use of Unrelated Cord Blood Grafts
19. A Randomized, Double-Blind, Phase III Study Comparing Proposed Biosimilar Rituximab (RTXM83) Versus Reference Rituximab, Both in Combination with CHOP, in the First Line Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
20. Markers of bone turnover in patients with type 1 Gaucher disease receiving long-term velaglucerase alfa enzyme replacement therapy
21. Therapeutic goals and normal clinical values achieved within 4 years of initiating velaglucerase alfa in treatment-naïve patients with Gaucher disease in phase 3 studies
22. Two-Year Efficacy And Safety Of Velaglucerase Alfa In Patients With Type 1 Gaucher Disease Switching From Imiglucerase: Phase III Trial HGT-GCB-039 And Extension
23. 156. Enzyme replacement therapy with velaglucerase alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease
24. 157. Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in type 1 Gaucher disease: Positive results from a randomized, double-blind, global, phase III study
25. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.